Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IONS Ionis Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: IONS
Price (delayed)
$39.51
Market cap
$6.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.99
Enterprise value
$7.43B
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and
Highlights
IONS's quick ratio is up by 29% year-on-year and by 13% since the previous quarter
The company's debt fell by 2.3% YoY
The company's equity has surged by 60% YoY but it fell by 19% QoQ
The net income has declined by 19% year-on-year
Ionis Pharmaceuticals's EPS has decreased by 12% YoY
Key stats
What are the main financial stats of IONS
Market
Valuations
Earnings
Shares outstanding
159.16M
Market cap
$6.29B
Enterprise value
$7.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
13.2
Price to sales (P/S)
8.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.36
Revenue
$717.25M
Gross profit
$706.72M
Operating income
-$472.43M
Net income
-$458.03M
EBIT
-$372.89M
EBITDA
-$351.16M
Free cash flow
-$555.15M
Per share
Balance sheet
Liquidity
EPS
-$2.99
EPS diluted
-$2.99
Free cash flow per share
-$3.5
Book value per share
$2.99
Revenue per share
$4.52
TBVPS
$17.72
Total assets
$2.81B
Total liabilities
$2.34B
Debt
$1.41B
Equity
$475.73M
Working capital
$2.17B
Debt to equity
2.96
Current ratio
9.66
Quick ratio
8.73
Net debt/EBITDA
-3.26
Margins
Efficiency
Dividend
EBITDA margin
-49%
Gross margin
98.5%
Net margin
-63.9%
Operating margin
-65.9%
Return on assets
-15.8%
Return on equity
-92.1%
Return on invested capital
-9.9%
Return on capital employed
-14.6%
Return on sales
-52%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IONS stock price
How has the Ionis Pharmaceuticals stock price performed over time
Intraday
-0.73%
1 week
4.88%
1 month
17.91%
1 year
-17.1%
YTD
13.01%
QTD
30.96%
Financial performance
How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$717.25M
Gross profit
$706.72M
Operating income
-$472.43M
Net income
-$458.03M
Gross margin
98.5%
Net margin
-63.9%
The operating margin has declined by 32% year-on-year but it is up by 2.2% since the previous quarter
The company's net margin fell by 29% YoY
IONS's operating income is down by 21% year-on-year
The net income has declined by 19% year-on-year
Price vs fundamentals
How does IONS's price correlate with its fundamentals
Growth
What is Ionis Pharmaceuticals's growth rate over time
Valuation
What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
13.2
P/S
8.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.36
Ionis Pharmaceuticals's EPS has decreased by 12% YoY
The company's equity has surged by 60% YoY but it fell by 19% QoQ
The stock's price to book (P/B) is 12% more than its 5-year quarterly average of 11.8 but 3.6% less than its last 4 quarters average of 13.7
The P/S is 17% more than the last 4 quarters average of 7.5 and 9% more than the 5-year quarterly average of 8.0
IONS's revenue is down by 8% YoY
Efficiency
How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has decreased by 46% YoY
Ionis Pharmaceuticals's ROIC has decreased by 29% YoY
IONS's return on assets is down by 20% year-on-year
IONS's return on equity is up by 15% year-on-year and by 8% since the previous quarter
Dividends
What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IONS.
Financial health
How did Ionis Pharmaceuticals financials performed over time
The total assets is 20% greater than the total liabilities
The current ratio rose by 31% year-on-year and by 14% since the previous quarter
IONS's quick ratio is up by 29% year-on-year and by 13% since the previous quarter
The company's debt is 196% higher than its equity
The company's equity has surged by 60% YoY but it fell by 19% QoQ
Ionis Pharmaceuticals's debt to equity has decreased by 39% YoY but it has increased by 24% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.